Submission Details
| 510(k) Number | K220031 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 05, 2022 |
| Decision Date | August 04, 2023 |
| Days to Decision | 576 days |
| Submission Type | Traditional |
| Review Panel | Hematology (HE) |
| Summary | Summary PDF |
K220031 is an FDA 510(k) clearance for the Alinity h-series System, a Counter, Differential Cell (Class II — Special Controls, product code GKZ), submitted by Abbott Laboratories (Santa Clara, US). The FDA issued a Cleared decision on August 4, 2023, 576 days after receiving the submission on January 5, 2022. This device falls under the Hematology review panel. Regulated under 21 CFR 864.5220.
| 510(k) Number | K220031 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 05, 2022 |
| Decision Date | August 04, 2023 |
| Days to Decision | 576 days |
| Submission Type | Traditional |
| Review Panel | Hematology (HE) |
| Summary | Summary PDF |
| Product Code | GKZ — Counter, Differential Cell |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 864.5220 |